Mary Bird Perkins 2022 Logo
Search
Close this search box.

Wayne Newhauser, Ph.D.

Wayne Newhauser

EDUCATION AND TRAINING

Postdoctoral Fellow, 1993-1996
Physikalisch-Technische Bundesanstalt, Braunschweig,
Germany

Ph.D., Medical Physics, 1995
University of Wisconsin, Madison, WI

M.S., Medical Physics, 1991
University of Wisconsin, Madison, WI

B.S., Nuclear Engineering, 1987
University of Wisconsin, Madison, WI

EMPLOYMENT

Program Director, 2015-present
Lousiana State University Physics Department, Baton Rouge, LA

Chief of Physics, 2011-2015
Mary Bird Perkins Cancer Center, Baton Rouge, LA

Associate Professor, 2009-2011
University of Texas M.D. Anderson Cancer Center, Houston, TX

Assistant Professor, 2002-2009
University of Texas M.D. Anderson Cancer Center, Houston, TX

Assistant Professor, 1999-2002
Harvard Medical School, Boston, MA

Instructor, 1997-1999
Harvard Medical School, Boston, MA

CERTIFICATIONS

American Board of Radiology, 2008 – present
Therapeutic Radiological Physics

PEER-REVIEWED ORIGINAL RESEARCH ARTICLES

  1. Newhauser WD, Schrewe UJ, Wiegel B. Gas-to-wall absorbed dose conversion factors at neutron energies of 25 to 250 MeV. Radiat Prot Dosim 61:281-284, 1995.

  2. Schrewe UJ, Newhauser WD, Brede HJ, Gerdung S, Nolte R, Pihet P, Schmelzbach P, Schuhmacher H. Measurement of neutron kerma factors in C and O: neutron energy range of 20 MeV to 70 MeV. Radiat Prot Dosim 61:275-280, 1995.

  3. Schrewe UJ, Alberts W, Newhauser WD, Brede HJ, DeLuca Jr PM. Comparison of various dose quantities in tissue and tissue substitutes at neutron energies between 20 MeV and 100 MeV. Radiat Prot Dosim 68:17-20, 1997.

  4. Newhauser WD, Schrewe UJ. Gas-to-wall absorbed dose conversion factors at neutron energies of 25 MeV to 250 MeV. Atomic Data Nucl Data Tables 65:37-53, 1997.

  5. Newhauser WD, Brede HJ. Influence of cavity size on the response of cavity chambers to 25- and 45-MeV neutrons. Med Phys 24:527-533, 1997.

  6. Newhauser WD, Schrewe UJ, Brede HJ, DeLuca Jr PM. Kerma measurements in polyenergetic neutron fields. Radiat Prot Dosim 68:13-16, 1997.

  7. Newhauser WD, Brede HJ, Dangendorf V, Mannhart W, Meulders JP, Schrewe UJ, Schuhmacher H. Measurement of the 238U fission cross section at 34-MeV, 46-MeV, and 61-MeV neutron energies. Proceedings of an International Conference on Nuclear Data for Standards and Technology, held May 19-24, 1997 in Trieste, Italy. Italian Physical Society, Bologna 69:1236-1238, 1997.

  8. Schrewe UJ, Newhauser WD, Brede HJ, DeLuca Jr PM. Neutron kerma factor measurements in the energy range of 5 MeV to 65 MeV. Proceedings of an International Conference on Nuclear data for Standards and Technology, held May 19-24, 1997 in Trieste, Italy. Italian Physical Society, Bologna 69:1643-1645, 1997.

  9. Schuhmacher H, Brede HJ, Dangendorf V, Meuleders JP, Nolte R, Newhauser WD, Schrewe UJ. Quasi-monoenergetic reference neutron radiation fields with energies from 25 MeV to 7- MeV. Proceedings of an International Conference on Nuclear Data for Standards and Technology, held May 19-24, 1997 in Trieste, Italy. Italian Physical Society, Bologna 69:388-392, 1997.

  10. Vatnitsky S, Moyers M, Miller D, Abell G, Slater JM, Pedroni E, Coray A, Mazal A, Newhauser W, Jaekel O, Heese J, Fukumura A, Futami Y, Verhey L, Daftari I, Grusell E, Molokanov A, Bloch C. Proton dosimetry intercomparison based on the ICRU Report 59 protocol. Radiother Oncol 51:273-279, 1999.

  11. Schuhmacher H, Brede HJ, Dangendorf V, Kuhfuss M, Meulders JP, Newhauser WD, Nolte R. Quasi-monoenergetic neutron beams with energies from 25 MeV to 70 MeV. Nucl Instr Meth A421:284-295, 1999.

  12. Flanz JB, Bailey J, Bradley SG, Goitein M, Gottshalk B, Jongen Y, Loeffler J, Mandin J, Miyahara N, M WD, Prieels D, Rosenthal S, Rosselot D, Schippers M, Schubert J, Smith A, Wagner M. Recent performance of the NPTC equipment compared with the clinical specifications. Proceedings of the 15th International Conference on the Applications of Accelerators in Research and Industry, held Nov. 1998 in Denton OH. American Association of Physics, 1999.

  13. Kooy H, Oelfke U, Lomax T, Paganetti H, Newhauser W, Bortfeld T, Goitein M. Design considerations for intensity modulated proton therapy treatment planning. In: International Conference on the use of Computers in Radiation Therapy, 22-25 May 2000 in Heidelberg, Germany:71-72, 2000.

  14. Schrewe UJ, Newhauser WD, Brede HJ, DeLuca Jr PM. Experimental kerma coefficients of C, O, Mg, Al, Si, Fe, Zr, Al2O3, AlN, SiO2, and ZrO2 for Neutron Energies up to 70 MeV. Phys Med Biol 45:651-683, 2000.

  15. Titt U, Newhauser WD, Yan X, Dexheimer D. Neutron shielding calculations for a 230-MeV proton therapy facility. In: Advanced Monte Carlo for Radiation Physics, Particle Transport Simulation and Applications. Proceedings of the Monte Carlo 2000 Conference, Lisbon, 23-26 October 2000:1075-1080, 2001.

  16. Newhauser WD, Burns J, Smith AR. Dosimetry for ocular proton beam therapy at the Harvard Cyclotron Laboratory based on the ICRU Report 59. Med Phys 29:1953-1961, 2002.

  17. Nolte R, Saalih Allie M, Binns PJ, Brooks FD, Buffler A, Dangendorf V, Langen K, Muelders JP, Newhauser WD, Roos F, Schuhmacher H. Measurement of 235U, 38U, 209Bi and Pb fission cross sections using quasi-monoenergetic neutrons with energies from 30 MeV to 150 MeV. J Nucl Science Technol Supp 2:311-314, 2002.

  18. Yan X, Titt U, Koehler AM, Newhauser WD. Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field. Nucl Instr Meth A 476:429-434, 2002.

  19. Newhauser WD, Titt U, Dexheimer D, Yan X, Nill S. Neutron shielding verification measurements and simulations for a 235-MeV proton therapy center. Nucl Instr Meth A 476:80-84, 2002.

  20. Newhauser WD, Myers K, Rosenthal S, Smith AR. Proton beam dosimetry for radiosurgery: implementation of the ICRU Report 59 at the Harvard Cyclotron Laboratory. Phys Med Biol 47:1369-1389, 2002.

  21. Newhauser WD, Dexheimer DT, Titt U. Shielding of proton therapy facilities – A review of recent advances. In: Proc Am Nucl Soc Radiat Prof Shielding Division Conf. April 14-17, 2002, Santa Fe, NM, 2002.

  22. Smith AR, Newhauser WD, Latinkic M, Hay A, McMaken B, Styles J, Cox J. The University of Texas M. D. Anderson Cancer Center Proton Therapy Facility. 17th International Conference on the Application of Accelerators in Research and Industry, held November 12-16, 2002 in Denton, TX, 2003.

  23. Newhauser WD, Titt U, Dexheimer DT. A perspective on shielding design methods for future proton therapy facilities. In: Proc SATIF-6, held 10-12 April, 2002, Stanford, CA, OECD/NEA, Paris, 2004.

  24. Polf JC, Newhauser WD. Calculations of neutron dose equivalent exposures from range-modulated proton therapy beams. Phys Med Biol 50(16):3859-3873, 8/2005. e-Pub 8/2005.

  25. Newhauser W, Koch N, Hummel S, Ziegler M, Titt U. Monte Carlo simulations of a nozzle for the treatment of ocular tumours with high-energy proton beams. Phys Med Biol 50(22):5229-49, 11/2005. e-Pub 10/2005.

  26. Newhauser WD, Ding X, Giragosian D, Nill S, Titt U. A neutron radiation area monitoring system for proton therapy facilities. Radiat Prot Dosim 115:149-153, 2005.

  27. Fontenot J, Newhauser WD, Titt U. Design tools for proton therapy nozzles based on the double-scattering foil technique. Radiat Prot Dosim 116:211-215, 2005.

  28. Titt U, Newhauser WD. Neutron shielding in a proton therapy facility based on Monte Carlo simulations: the design method of choice. Radiat Prot Dosim 115:144-148, 2005.

  29. Polf JC, Newhauser WD, Titt U. Patient neutron dose equivalent exposures outside of the proton therapy treatment field. Radiat Prot Dosim 115:154-158, 2005.

  30. Mourtada F, Koch N, Newhauser WD. Ruthenium-106 eye plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study. Radiat Prot Dosim 116:454-460, 2005.

  31. Bues M, Newhauser WD, Titt U, Smith AR. Therapeutic step and shoot proton beam spot-scanning with a multi-leaf collimator: a Monte Carlo study. Radiat Prot Dosimetry 115:164-169, 2005.

  32. Koch N, Newhauser WD. Virtual commissioning of an ocular treatment planning system. Radiat Prot Dosim 115:159-163, 2005.

  33. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys 68(5):1529-36, 8/2007.

  34. Newhauser W, Fontenot J, Zheng Y, Polf J, Titt U, Koch N, Zhang X, Mohan R. Monte Carlo simulations for configuring and testing an analytical treatment planning system. Phys Med Biol 52(15):4569-4584, 8/2007. e-Pub 7/2007.

  35. Polf JC, Harvey MC, Titt U, Newhauser WD, Smith AR. Initial beam size study for passive scatter proton therapy. I. Monte Carlo verification. Med Phys 34(11):4213-8, 11/2007.

  36. Melancon AD, O’Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 85(2):251-9, 11/2007.

  37. Fontenot JD, Newhauser WD, Bloch C, White RA, Titt U, Starkschall G. Determination of output factors for small proton therapy fields. Med Phys 34(2):489-498, 2007.

  38. Newhauser WD, Koch NC, Fontenot JD, Rosenthal SJ, S Gombos D, Fitzek MM, Mohan R. Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy. Phys Med Biol 52(13):3979-3990, 2007.

  39. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 67(2):620-629, 2007.

  40. Zheng Y, Newhauser WD, Fontenot JD, Koch N, and Mohan R. Monte Carlo simulation model of the M. D. Anderson Cancer Centers passively scattered proton therapy machine. J Nucl Matl 361:289-297, 2007.

  41. Newhauser W, Fontenot J, Koch N, Dong L, Lee A, Zheng Y, Waters L, Mohan R. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol 52(11):2937-2952, 2007.

  42. Zheng Y, Newhauser W, Fontenot J, Taddei P, Mohan R. Monte Carlo study of neutron dose equivalent during passive scattering proton therapy. Phys Med Biol 52(15):4481-4496, 2007.

  43. Titt U, Zheng Y, Vassiliev ON, Newhauser WD. Monte Carlo investigation of collimator scatter of proton-therapy beams produced using the passive scattering method. Phys Med Biol 53(2):487-504, 1/2008. e-Pub 12/2007.

  44. Zheng Y, Fontenot J, Taddei P, Mirkovic D, Newhauser W. Monte Carlo simulations of neutron spectral fluence, radiation weighting factor and ambient dose equivalent for a passively scattered proton therapy unit. Phys Med Biol 53(1):187-201, 1/2008. e-Pub 12/2007.

  45. Fontenot J, Taddei P, Zheng Y, Mirkovic D, Jordan T, Newhauser W. Equivalent dose and effective dose from stray radiation during passively scattered proton radiotherapy for prostate cancer. Phys Med Biol 53(6):1677-88, 3/2008. e-Pub 2/2008.

  46. Koch N, Newhauser WD, Titt U, Gombos D, Coombes K, Starkschall G. Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy. Phys Med Biol 53(6):1581-94, 3/2008. e-Pub 2/2008.

  47. Taddei PJ, Fontenot JD, Zheng Y, Mirkovic D, Lee AK, Titt U, Newhauser WD. Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer. Phys Med Biol 53(8):2131-47, 4/2008. e-Pub 3/2008.

  48. Newhauser WD, Giebeler A, Langen KM, Mirkovic D, Mohan R. Can megavoltage computed tomography reduce proton range uncertainties in treatment plans for patients with large metal implants? Phys Med Biol 53(9):2327-2344, 5/2008. e-Pub 4/2008.

  49. Titt U, Sahoo N, Ding X, Zheng Y, Newhauser WD, Zhu XR, Polf JC, Gillin MT, Mohan R. Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions. Phys Med Biol 53(16):4455-70, 8/2008. e-Pub 7/2008.

  50. Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, Cox JD, Hui Z, Li Y, Newhauser WD, Mohan R, Liao Z. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72(1):278-287, 9/2008. PMCID: PMC2610812.

  51. Newhauser WD. Book Review: International Commission on Radiation Units and Measurements Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. Radiat Prot Dosim 133(1):60-62, 1/2009.

  52. Pérez-Andújar A, Newhauser WD, Deluca PM. Contribution to Neutron Fluence and Neutron Absorbed Dose from Double Scattering Proton Therapy System Components. Nucl Technol 168(3):728-735, 1/2009. PMCID: PMC2943637.

  53. Yepes P, Randeniya S, Taddei PJ, Newhauser WD. Monte Carlo Fast Dose Calculator for proton radiotherapy: application to a voxelized geometry representing a patient with prostate cancer. Phys Med Biol 54(1):N21-N28, 1/2009. e-Pub 12/2008.

  54. Pérez-Andújar A, Newhauser WD, Deluca PM. Neutron production from beam-modifying devices in a modern double scattering proton therapy beam delivery system. Phys Med Biol 54(4):993-1008, 2/2009. e-Pub 1/2009.

  55. Zhang R, Newhauser WD. Calculation of water equivalent thickness of materials of arbitrary density, elemental composition and thickness in proton beam irradiation. Phys Med Biol 54(6):1383-95, 3/2009. e-Pub 2/2009.

  56. Newhauser WD, Fontenot JD, Taddei PJ, Mirkovic D, Giebeler A, Zhang R, Mahajan A, Kornguth D, Stovall M, Yepes P, Woo S, Mohan R. Contemporary proton therapy systems adequately protect patients from exposure to stray radiation. AIP Conf Proc 1099(1):450-455, 3/2009. PMCID: PMC2939014.

  57. Taddei PJ, Krishnan S, Mirkovic D, Yepes P, Newhauser WD. Effective dose from stray radiation for a patient receiving proton therapy for liver cancer. AIP Conf Proc 1099:445-449, 3/2009. PMCID: PMC2943390.

  58. Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Kornguth D, Mohan R, Newhauser WD. Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol 54(8):2259-2275, 4/2009. e-Pub 3/2009.

  59. Newhauser WD, Fontenot JD, Mahajan A, Kornguth D, Stovall M, Zheng Y, Taddei PJ, Mirkovic D, Mohan R, Cox JD, Woo S. The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol 54(8):2277-2297, 4/2009. e-Pub 3/2009.

  60. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 74(2):616-22, 6/2009.

  61. Fontenot JD, Taddei P, Zheng Y, Mirkovic D, Newhauser WD. Ambient dose equivalent versus effective dose for quantifying stray radiation exposures to a patient receiving proton therapy for cancer of the prostate. Nucl Technol 168:173-177, 10/2009.

  62. Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Titt U, Woo S, Newhauser WD. Reducing stray radiation dose for a pediatric patient receiving proton craniospinal irradiation. Nucl Technol 168:108-112, 10/2009.

  63. Zheng Y, Newhauser W, Klein E, Low D. Monte Carlo simulation of the neutron spectral fluence and dose equivalent for use in shielding a proton therapy vault. Phys Med Biol 54(22):6943-57, 11/2009. e-Pub 11/2009.

  64. Yepes P, Randeniya S, Taddei PJ, Newhauser WD. A track repeating algorithm for fast Monte Carlo dose calculations of proton radiotherapy: a case study for cancer of prostate. Nucl Technol 168(3):173-177, 12/2009.

  65. Randeniya SD, Taddei PJ, Newhauser WD, Yepes P. Intercomparision of Monte Carlo Radiation Transport Codes MCNPX, GEANT4, and FLUKA for Simulating Proton Radiotherapy of the Eye. Nucl Technol 168(3):810-814, 12/2009. PMCID: PMC2943388.

  66. Giebeler A, Fontenot J, Balter P, Ciangaru G, Zhu R, Newhauser W. Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer. J Appl Clin Med Phys 10(1):63-70, 2009. e-Pub 1/2009. PMCID: PMC2949274.

  67. Koch NC, Newhauser WD. Development and verification of an analytical algorithm to predict absorbed dose distributions in ocular proton therapy using Monte Carlo simulations. Phys Med Biol 55(3):833-53, 2/2010. e-Pub 1/2010.

  68. Zhang R, Taddei PJ, Fitzek MM, Newhauser WD. Water equivalent thickness values of materials used in beams of protons, helium, carbon and iron ions. Phys Med Biol 55(9):2481-93, 5/2010. e-Pub 4/2010. PMCID: PMC2977971.

  69. Titt U, Mirkovic D, Sawakuchi GO, Perles LA, Newhauser WD, Taddei PJ, Mohan R. Adjustment of the lateral and longitudinal size of scanned proton beam spots using a pre-absorber to optimize penumbrae and delivery efficiency. Phys Med Biol 55(23):7097-106, 12/2010. e-Pub 11/2010. PMCID: PMC3001334.

  70. Zhang R, Pérez-Andújar A, Fontenot JD, Taddei PJ, Newhauser WD. An analytic model of neutron ambient dose equivalent and equivalent dose for proton radiotherapy. Phys Med Biol 55(23):6975-85, 12/2010. e-Pub 11/2010. PMCID: PMC3001300.

  71. Yepes PP, Brannan T, Huang J, Mirkovic D, Newhauser WD, Taddei PJ, Titt U. Application of a fast proton dose calculation algorithm to a thorax geometry. Radiat Meas 45(10):1367-1368, 12/2010. PMCID: PMC3085469.

  72. Taddei PJ, Chell E, Hansen S, Gertner M, Newhauser WD. Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration. Phys Med Biol 55(23):7037-54, 12/2010. e-Pub 11/2010. PMCID: PMC3001331.

  73. Cheung J, Kudchadker RJ, Zhu XR, Lee AK, Newhauser WD. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer. Phys Med Biol 55(23):7135-47, 12/2010. e-Pub 11/2010.

  74. Fontenot JD, Bloch C, Followill D, Titt U, Newhauser WD. Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy. Phys Med Biol 55(23):6987-98, 12/2010. e-Pub 11/2010.

  75. Howell RM, Scarboro SB, Taddei PJ, Krishnan S, Kry SF, Newhauser WD. Methodology for determining doses to in-field, out-of-field, and partially in-field organs for late effects studies in photon radiotherapy. Phys Med Biol 55(23):7009-23, 12/2010. e-Pub 11/2010. PMCID: PMC3001332.

  76. Taddei PJ, Mahajan A, Mirkovic D, Zhang R, Giebeler A, Kornguth D, Harvey M, Woo S, Newhauser WD. Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. Phys Med Biol 55(23):7067-80, 12/2010. e-Pub 11/2010. PMCID: PMC3001324.

  77. Taddei PJ, Howell RM, Krishnan S, Scarboro SB, Mirkovic D, Newhauser WD. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol 55(23):7055-65, 12/2010. e-Pub 11/2010. PMCID: PMC3001302.

  78. Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 11(6):438-48, 6/2011. e-Pub 5/2011.

  79. Vadapalli R, Yepes P, Newhauser W, Lichti R. Grid-enabled treatment planning for proton therapy using Monte Carlo simulations. Nucl Technol 175(1):16-21, 7/2011.

  80. Huang JY, Newhauser WD, Zhu XR, Lee AK, Kudchadker RJ. Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate. Phys Med Biol 56(16):5287-302, 8/2011. e-Pub 7/2011.

  81. Newhauser WD, Scheurer ME, Faupel-Badger JM, Clague J, Weitzel J, and Woods KV.  The Future Workforce in Cancer Prevention: Advancing Discovery, Research, and Technology, J. Cancer Educ Suppl 2:S128-35 (2012).

  82. Howell, Giebeler,Koontz-Raisigc, Mahajan, Etzel, D’Amelio, Randeniya , Newhauser. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiother Oncol. 2012 Jul 24;7(1):116.

  83. Rechner, Howell, Zhang, Etzel, Lee, Newhauser. Risk of radiogenic second cancers following volumetric-modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol. Phys. Med. Biol. 57 7117-7132 (2012).

  84. Rechner L, Howell R, Zhang R, Newhauser WD. Impact of margin size on the predicted risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol Phys Med Biol. 2012 Dec 7;57(23):N469-79.

  85. Giebeler, Howell, Amos, Mahajan, Newhauser. Standardized treatment planning methodology for passively scattered proton craniospinal irradiation and consistency between individually optimized plans. Radiother Oncol. (2013).

  86. Zhang, Fontenot, Mirkovic, Hendricks, Newhauser. Advantages of MCNPX-based lattice tally over mesh tally in high-speed Monte Carlo dose reconstruction for proton radiotherapy. Nucl Technol. 183(1) 101-106 (2013).

  87. Zhang, Howell, Giebeler, Taddei, Mahajan, Newhauser. Predicted risk of radiogenic cardiac toxicity in a pediatric medulloblastoma patient treated with photon and proton craniospinal irradiation. Radiother Oncol. Radiation Oncology 2013, 8:184 2013.

  88. Perez-Andujar, Howell, Taddei, Mahajan, Newhauser. Predicted relative risk of sterility for three radiotherapy modalities for a girl receiving craniospinal irradiation. Phys Med Biol Phys Med Biol. 2013 May 21;58(10):3107-23.

  89. Newhauser WD, Rechner L, Mirkovic D, Yepes P, Koch NC, Titt U, Fontenot JD, Zhang R.  Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams.  Radiation Measurements, Volume 58, November 2013, Pages 37-44, ISSN 1350-4487, http://dx.doi.org/10.1016/j.radmeas.2013.08.001.

  90. Taddei PJ, ,Jalbout W, Howell RM, Khater N, Geara F, Homann K, and Newhauser WD.  Analytical model for out-of-field dose in photon craniospinal irradiation.  Phys Med Biol. 8(21), 7463 2013

  91. Zhang, Howell, Giebeler, Taddei, Mahajan, Newhauser. Comparison of risk of radiogenic second cancer between photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Phys Med Biol. 2013 Feb 21;58(4):807-23. doi: 10.1088/0031-9155/58/4/807.

  92. Perez-Andujar A, Zhang R, Taddei P, Newhauser WD. Prediction of neutron dose equivalent dose source terms for radioprotection in proton therapy.  Med. Phys 40, 121714 (2013)

  93. Eley JG, Newhauser WD, Lüchtenborg R, Graeff C, and Bert C.  4D Optimization of for Scanned Ion Beam Tracking Therapy of Moving Tumors. Phys Med Biol 59 3431–3452 (2014)

  94. Newhauser WD, Jones T, Swerdloff S, Newhauser WA, Cilia M, Carver R, Halloran R, Zhang R. Anonymization of DICOM electronic medical records for radiation therapy, Comp Biol Med. 53 134-140 (2014)

  95. Zhang R, Howell R, Taddei PJ, Giebeler A, Mahajan A, Newhauser WD.  A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation.  Radiother Oncol, 113 84-88, 2014.

  96. Eley JG, Newhauser WD, Richter D, Lüchtenborg R, Saito N, Bert C.  Robustness of target dose coverage to motion uncertainties for scanned carbon ion beam tracking therapy of moving tumors.  Phys. Med. Biol.  60:1717-40, 2015. http://stacks.iop.org/0031-9155/60/1717

  97. Taddei PJ, Khater N, Zhang R, Geara FB, Mahajan A, Jalbout W, Pérez-Andújar A, Youssef B, Newhauser WD.  Inter-institutional comparison of personalized risk assessments for second malignant neoplasms for a 13-year-old girl receiving proton versus photon craniospinal irradiation. Cancers 7, 407-426 (2015) doi:10.3390/cancers7010407.

  98. Eley J, Newhauser W, Homann K, Howell R, Durante M, Bert C.  Implementation of an analytical model for neutron equivalent dose in a proton radiotherapy treatment planning system. Cancers 7, 427-438 (2015); doi:10.3390/cancers7010427.

  99. Rechner L, Zhang R, Eley J, Howell R, Mirkovic D, Newhauser WD.  Minimization of the incidence of radiogenic second cancers with risk-optimized proton therapy, Phys Med Biol, 60 3999–4013 (2015).

  100. Newhauser WD and Zhang R, The physics of proton therapy, Phys Med Biol. 60 (2015) R155–R209.

  101. Freund D, Zhang R, Sanders M, and Newhauser W.  Predictive Risk of Radiation Induced Cerebral Necrosis in Pediatric Brain Cancer Patients after VMAT Versus Proton Therapy. Cancers, 7, 617-630, 2015; doi:10.3390/cancers7020617.

  102. Newhauser W, Zhang R, Jones T, Giebeler A, Taddei P, Stewart R, Lee A, Vassiliev O.  Reducing the cost of proton radiation therapy: The feasibility of a streamlined treatment technique for prostate cancer.  Cancers, 2015, 7, 688-705.

  103. Schneider, C. Newhauser WD, Farah J.  An analytical model of leakage neutron equivalent dose for passively-scattered proton therapy and validation with measurements. Cancers 7, 795-810 (2015).

  104. Jagetic L and Newhauser WD, A simple and fast analytical method to calculate doses to the whole body from external beam, megavoltage x-ray therapy. Phys Med Biol. 60 (2015) 4753–4775.

  105. Zhang R, Mirkovic D, and Newhauser WD.  Visualization of risk of radiogenic second cancer in the organs and tissues of the human body.  Radiat Oncol J. (2015) 10:107, DOI 10.1186/s13014-015-0404-x

  106. Newhauser WD, Giebeler A, Zhu R, Titt U, Lee AK, Zhang R.  Uncertainty in dose per monitor unit estimates for passively scattered proton therapy, Part I: The role of compensator and patient scatter in prostate cases, Proton Therapy Journal, 1:1 1 (2015).  >4

  107. Newhauser WD, Berrington de Gonzalez A, Schulte R, and Lee C.  A Review of Radiotherapy-Induced Late Effects Research After Advanced-Technology Treatments.  (Invited review), Frontiers in Oncology. Vol 6, article 13 (2016).

  108. Hernandez M, Zhang R, Sanders M, Newhauser W.  A treatment planning comparison of volumetric modulated arc therapy and proton therapy for a sample of breast cancer patients treated with post-mastectomy radiotherapy. J Proton Therapy, 1:1 1-7 (2016)

  109. Homann K, Howell R, Eley J, Mirkovic D, Etzel C, Giebeler A, Mahajan A, Zhang R, Newhauser W. The need for individualized studies to compare radiogenic second cancer (RSC) risk in proton versus photon Hodgkin Lymphoma patient treatments. J Proton Therapy, 1:1 1-11 (2015). (actually published in 2016, not 2015 as listed)

  110. Eley J, Friedrich T, Homann K, Howell R, Scholz M, Durante M, Newhauser WD.  Comparative Risk Predictions of Second Cancers after Carbon-Ion Therapy versus Proton Therapy, IJROBP, Volume 95, Issue 1, 1 May 2016, Pages 279–286.

  111. Donahue W, Ziegler, JF, and Newhauser WD.  Analytical model for ion stopping power and range in the therapeutic energy interval for beams of hydrogen and heavier ions, Phys Med Biol, 61 (2016) 6570–6584 (2016).

  112. Newhauser, WD.  The medical physics workforce. (invited review)  Health Physics Journal, (at press).